| [1] |
Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future[J]. Semin Cancer Biol, 2011, 21(1):59-69.
|
| [2] |
Furtado R, Crawford M, Sandroussi C. Systematic review and meta-analysis of adjuvant I 131 lipiodol after excision of hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, DOI: 10.1245/s10434-014-3511-2[Epub ahead of print]. |
| [3] |
刘波，杨扬．肝细胞肝癌肿瘤新生血管与肝癌治疗[J/CD]．中华肝脏外科手术学电子杂志，2013, 2(4):267-269.
|
| [4] |
Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives[J]. Semin Oncol, 2012, 39(4):493-502.
|
| [5] |
Raoul J, Santoro A, Beaugrand M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial[J]. J Clin Oncol, 2008, 26(15S):4587.
|
| [6] |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
|
| [7] |
Yamamoto C, Yagi S, Hori T, et al. Significance of portal venous VEGF during liver regeneration after hepatectomy[J]. J Surg Res, 2010, 159(2):e37-e43.
|
| [8] |
Minata M, Harada KH, Kudo M, et al. The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection[J]. Oncology, 2013, 84(Suppl 1):75-81.
|
| [9] |
Di Marco V, De Vita F, Koskinas J, et al. Sorafenib: from literature to clinical practice[J]. Ann Oncol, 2013, 24(Suppl 2):ii30-ii37.
|
| [10] |
黄超有，张红卫，聂向阳，等．索拉非尼对肝切除术后早期肝再生影响的研究[J]．广西医学，2013, 35(7):838-841.
|
| [11] |
Guo JH, Zhu X, Li XT, et al. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization[J]. Chin J Cancer Res, 2012, 24(1):36-43.
|
| [12] |
Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature[J]. Dig Dis Sci, 2013, 58(12):3389-3396.
|
| [13] |
Li Y, Zheng YB, Zhao W, et al. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma[J]. Med Oncol, 2013, 30(4):730.
|
| [14] |
Kudo M, Imanaka K, Chida N, et al. Phase Ⅲ study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14):2117-2127.
|
| [15] |
Mertens JC, Martin IV, Schmitt J, et al. Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals[J]. Eur J Radiol, 2012, 81(7):1601-1606.
|
| [16] |
Erös de Bethlenfalva-Hora C, Mertens JC, Piguet AC, et al. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma[J]. Clin Sci, 2014, 126(3):243-252.
|
| [17] |
Xu M, Xie XH, Xie XY, et al. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo[J]. Acta Radiol, 2013, 54(2):199-204.
|
| [18] |
Printz C. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM)[J]. Cancer, 2009, 115(20):4646.
|